Cyclacel Pharmaceuticals (CYCC) 0.80 0.00

Cyclacel Pharmaceuticals, Inc.
(CYCC) 0.80 0.00

Last Trade:	0.601	Day Range:	0.601 - 0.601
Trade Time:	08:02PM	52wk Range:	0.36 - 1.84
Prev. Close:	0.601	Market Cap:	32.59M
Open:	0.00	Div Yield:
Volume:	124339	PE:
EPS:	-0.30

The Latest On CYCC

Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes 2/13/12 7:00am

Benzinga's Microcap Movers for Monday February 6, 2012 2/6/12 9:51pm

Cyclacel Provides Corporate Update at OneMedForum Conference; Re-Analysis "Insufficient" 1/11/12 12:27pm

Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML 12/12/11 1:02pm

Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch 12/7/11 1:31pm

Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients 12/7/11 7:02am

Earnings Scheduled For November 14 11/14/11 4:24am

Cyclacel Pharmaceuticals Jumps; Breaks Above Resistance 10/19/11 1:21pm

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine 10/13/11 6:05am

Cyclacel Pharmaceuticals Receives Deficiency Notice From Nasdaq Global Select Market 9/22/11 3:03pm

Hearing Cyclacel Pharma Drug Effective on Breast Cancer Tumors 8/15/11 9:33am

The Biotech Bump: Cyclacel Pharmaceuticals 7/28/11 12:57pm

Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes 2/13/12

Benzinga's Microcap Movers for Monday February 6, 2012 2/6/12

Cyclacel Provides Corporate Update at OneMedForum Conference; Re-Analysis "Insufficient" 1/11/12

Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML 12/12/11

Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch 12/7/11

Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients 12/7/11

Earnings Scheduled For November 14 11/14/11

Cyclacel Pharmaceuticals Jumps; Breaks Above Resistance 10/19/11

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine 10/13/11

Cyclacel Pharmaceuticals Receives Deficiency Notice From Nasdaq Global Select Market 9/22/11

Hearing Cyclacel Pharma Drug Effective on Breast Cancer Tumors 8/15/11

The Biotech Bump: Cyclacel Pharmaceuticals 7/28/11

Benzinga's Microcap Movers for Monday February 6, 2012 2/6/12

Cyclacel Pharmaceuticals Jumps; Breaks Above Resistance 10/19/11

The Biotech Bump: Cyclacel Pharmaceuticals 7/28/11

Cyclacel Pharmaceuticals Could See Continued Interest As A Result Of Its Radiation Cream (CYCC) 3/23/11

Benzinga’s Top Pre-Market Losers (SEED, MPGI, CYCC, NFLX, ROSG, PEIX) 1/14/10

This Week's Most-Purchased Stocks to Date - AA, CYCC, F, C 1/12/10

CYCC Shares Continue To Stand Out In Pre-Market Trading 1/8/10

Trade CYCC
NOW!

Partner Headlines

BIO CEO Conference Live Blog 2/13/12

The Worst Biotech CEO of 2011 Is ... 12/9/11

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling 11/16/11

Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-Q) 11/14/11

Biotech Stock Mailbag: Somaxon, Transcept 10/7/11

Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks 9/30/11

Biotech Stock Mailbag: Cyclacel Pharma 8/12/11

Biotech Stock Mailbag: Ranking Cheap Biotechs 7/1/11

10 Cheap Biotech Stocks That Could Soar 6/28/11

ASCO: Traders Love Speculative Cancer Stocks 5/19/11

Biotech Stock Mailbag: Bio-Hazards 3/25/11

Press Releases

Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes 2/13/12 GlobeNewswire Story

Cyclacel to Present at Upcoming Investor Conferences 2/6/12 GlobeNewswire Story

Cyclacel Provides Corporate Update at OneMedForum Conference 1/11/12 GlobeNewswire Story

Cyclacel to Present at the 5th Annual OneMedForum in San Francisco 1/6/12 GlobeNewswire Story

Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML 12/12/11 GlobeNewswire Story

Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients 12/7/11 GlobeNewswire Story

Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011 12/1/11 GlobeNewswire Story

Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results 11/14/11 GlobeNewswire Story

Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events 11/7/11 GlobeNewswire Story

Chris Henney Receives 2011 Hall of Fame Award at Annual Biotech CEO Meeting at Laguna Beach 10/17/11 Newswire Story

Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2011 Financial Results 8/30/11 GlobeNewswire Story

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine 8/30/11 GlobeNewswire Story

Get the latest CYCC stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Cyclacel Pharmaceuticals, Inc. stock price.

Cyclacel Pharmaceuticals, Inc. by YCharts